Serum levels of vascular endothelial growth factor-D (VEGF-D), a ligand for the lymphatic growth-factor receptor VEGFR-3/Flt-4, are higher in most LAM patients than in healthy controls or in patients with other cystic lung diseases (OCLD) (5, 6). This evidence concerns the gene FLT4 and lymphangioleiomyomatosis.